Scientists have identified which immune cells appear to produce the misdirected antibodies that show up in some people after a COVID-19 infection, and the pathway they describe overlaps with one already familiar to researchers who study lupus.
The finding is mechanistic rather than clinical. It does not mean COVID causes lupus, and it does not change how anyone is diagnosed or treated today. What it offers is a specific biological explanation for something clinicians have observed since early in the pandemic without being able to account for.
Autoantibodies are proteins the immune system produces that mistakenly target a person's own tissues instead of an invading pathogen. The immune system normally makes antibodies to find and destroy bacteria and viruses. Sometimes that process misfires. In people infected with the virus, autoantibodies have been linked to severe illness, persistent symptoms and an increased risk of newly developing autoimmune disease.
The Cells That Appear to Be Doing the Damage
Researchers at the Institute for Systems Biology in Seattle and their partners analyzed data from 209 people infected with the virus. From that group, they selected twelve age-matched women with markedly different autoantibody levels and sorted them into a high-autoantibody group and a low-autoantibody group for detailed analysis. A separate group of 101 participants was used to check the key results.
Atypical memory B cells were more likely to develop into autoantibody-secreting cells in the high group than in the low group. Within that population, a subtype called double-negative 2 B cells, usually shortened to DN2, was overrepresented in the high-autoantibody group. DN2 cells have previously been linked to autoantibody production and may play a role in other autoimmune diseases, including lupus.
Senior author Jim Heath, president of the institute, said the aim was to understand "why some people produce autoantibodies after SARS-CoV-2 infection while others do not," in a statement issued by the institute and reported by the University of Minnesota's infectious disease center. The team combined several layers of biological data to identify the cells involved and the mechanisms regulating them.
Lead author Dan Yuan said the results suggest infection can activate an immune program closely resembling those involved in established autoimmune disorders, which helps explain why some people experience autoimmune complications afterward.
Twelve Participants Is the Most Important Number Here
The deep analysis rests on twelve people. That is the figure readers should hold onto when they encounter this study in headlines elsewhere.
Small, intensively characterized groups are standard and appropriate in this kind of immunology, where the goal is to describe a mechanism rather than measure how common something is. But a twelve-person comparison cannot tell anyone how many people develop these autoantibodies, who is likely to, or what the consequences are over time. The validation group of 101 participants strengthens specific findings without changing that limit.
The samples also come from a particular moment. Data were collected in April 2021, before the Omicron variant emerged and before participants had been vaccinated. The immune landscape has shifted substantially since then through vaccination, repeat infection, and viral evolution. Whether the same pattern holds in people infected today is not something this work establishes.
The participants selected for detailed analysis were all women, chosen because autoantibody prevalence is higher in women and older adults. That makes the design sensible and also means the findings have not been shown to apply equally to men.
The work was published in the journal Immunity.
The Practical Meaning for Someone Recovering from COVID
Nobody should read this and conclude they are developing an autoimmune disease. The presence of autoantibodies is not the same as having lupus, which has its own recognized signs and symptoms, or any other named condition, and most people who produce them do not go on to develop autoimmune illness.
There is no test a person should now seek out. Autoantibody panels ordered without a clinical reason produce findings that are difficult to interpret and can lead to unnecessary follow-up, anxiety and cost. Testing decisions belong with a clinician evaluating actual symptoms.
People who have persistent symptoms after a COVID infection, including joint pain, unexplained rashes, prolonged fatigue, or new sensitivity to sunlight, should describe them to a clinician and mention the prior infection. Those are the circumstances in which evaluation for autoimmune disease is reasonable. Vague fatigue alone in an otherwise well person is not.
The most concrete near-term implication is for research rather than care. Yuan said the findings point to specific immune pathways that could become future therapeutic targets, and that understanding how these cells become activated moves the field closer to interventions that could prevent or reduce harmful autoimmune responses following infection.
The Distance Between a Pathway and a Treatment
That distance is long, and it is worth being honest about. Identifying a cell population and the regulatory mechanism behind it is an early step. It does not mean a drug is in development, that a clinical trial is planned, or that any existing lupus medication should be considered for people with post-COVID autoantibodies.
What the study does supply is a target. Researchers who want to test whether blocking a particular pathway reduces autoantibody production now know where to aim, which is a meaningful improvement over observing an association and having nowhere to go with it.
The next developments to watch are attempts to reproduce the finding in larger and more diverse groups, including men, vaccinated people, and those infected with more recent variants. Until that happens, this remains a well-executed piece of mechanistic biology from a small sample rather than a basis for changing anything about personal health decisions.
Key Questions Answered
What are autoantibodies? Proteins produced by the immune system that mistakenly target a person's own tissues rather than a pathogen. They have been linked to severe COVID illness, persistent symptoms, and increased risk of new autoimmune disease.
What did the researchers find? Atypical memory B cells, particularly a subtype called DN2, were more likely to become autoantibody-producing cells in people with high autoantibody levels. DN2 cells have also been linked to lupus.
Does this mean COVID causes lupus? No. The study describes a shared immune pathway. It does not show that infection causes lupus or any other named autoimmune disease.
How many people were studied? Data came from 209 infected participants, with twelve age-matched women analyzed in depth and a separate group of 101 used for validation.
Why does the timing of the samples matter? Samples were collected in April 2021, before Omicron and before the participants were vaccinated. Whether the same pattern appears in people infected today has not been shown.
Should I get tested for autoantibodies? Not on the basis of this study. Testing without a clinical reason produces results that are hard to interpret. Discuss persistent symptoms with a clinician instead.
What happens next? Researchers say the identified pathways could become future therapeutic targets. Replication in larger and more diverse groups, including men and vaccinated people, is the next step.
